{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:28:27Z","timestamp":1786339707288,"version":"build-2736575974"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"DOI":"10.1007\/s00405-026-10491-7","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:42:31Z","timestamp":1786336951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hearing loss in hyperthyroid patients treated with teprotumumab (TepezzaR)"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8943-3768","authenticated-orcid":false,"given":"Murilo","family":"de Santana Hager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0366-7239","authenticated-orcid":false,"given":"Paula Valeria","family":"Guerra Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7047-8164","authenticated-orcid":false,"given":"Ryan","family":"Dewan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Favre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-4907","authenticated-orcid":false,"given":"Mohamed","family":"Elrakhawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7406-4467","authenticated-orcid":false,"given":"Michele M.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"12","key":"10491_CR1","doi-asserted-by":"publisher","first-page":"3704","DOI":"10.1210\/clinem\/dgaa646","volume":"105","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly GJ (2020) Management of Graves thyroidal and extrathyroidal disease: an update. J Clin Endocrinol Metab 105(12):3704\u20133720. https:\/\/doi.org\/10.1210\/clinem\/dgaa646","journal-title":"J Clin Endocrinol Metab"},{"key":"10491_CR2","doi-asserted-by":"publisher","first-page":"615993","DOI":"10.3389\/fendo.2020.615993","volume":"11","author":"L Bartalena","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D et al (2020) Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol (Lausanne) 11:615993. https:\/\/doi.org\/10.3389\/fendo.2020.615993","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10491_CR3","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"R Douglas","year":"2020","unstructured":"Douglas R, Kahaly G, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382(4):341\u2013352. https:\/\/doi.org\/10.1056\/NEJMoa1910434","journal-title":"N Engl J Med"},{"key":"10491_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fendo.2016.00167","volume":"7","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Janssen JA (2016) Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy. Front Endocrinol (Lausanne) 7:167. https:\/\/doi.org\/10.3389\/fendo.2016.00167","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10491_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","volume":"240","author":"CM Sears","year":"2022","unstructured":"Sears CM, Azad AD, Amarikwa L et al (2022) Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol 240:1\u201313. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.015","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10491_CR6","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1097\/MAO.0000000000003428","volume":"43","author":"AS Ding","year":"2022","unstructured":"Ding AS, Mahoney NR, Campbell AA et al (2022) Sensorineural hearing loss after teprotumumab therapy for thyroid eye disease: a case report. Otol Neurotol 43(2):e148\u2013e152. https:\/\/doi.org\/10.1097\/MAO.0000000000003428","journal-title":"Otol Neurotol"},{"issue":"4","key":"10491_CR7","doi-asserted-by":"publisher","first-page":"e248335","DOI":"10.1136\/bcr-2021-248335","volume":"15","author":"A Chow","year":"2022","unstructured":"Chow A, Silkiss RZ (2022) Teprotumumab-associated chronic hearing loss screening and proposed treatments. BMJ Case Rep 15(4):e248335. https:\/\/doi.org\/10.1136\/bcr-2021-248335","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10491_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/thy.2023.0466","volume":"34","author":"RS Douglas","year":"2024","unstructured":"Douglas RS, Parunakian E, Tolentino J et al (2024) A prospective study examining audiometry outcomes following teprotumumab treatment for thyroid eye disease. Thyroid 34(1):134\u2013137. https:\/\/doi.org\/10.1089\/thy.2023.0466","journal-title":"Thyroid"},{"issue":"1","key":"10491_CR9","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ophtha.2023.08.001","volume":"131","author":"JA Keen","year":"2024","unstructured":"Keen JA, Correa T, Pham C et al (2024) Frequency and patterns of hearing dysfunction in patients treated with teprotumumab. Ophthalmology 131(1):30\u201336. https:\/\/doi.org\/10.1016\/j.ophtha.2023.08.001","journal-title":"Ophthalmology"},{"issue":"10","key":"10491_CR10","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3390\/jcm12103485","volume":"12","author":"LE Bertagnoli","year":"2023","unstructured":"Bertagnoli LE, Seist R, Batts S et al (2023) Potential ototoxicity of insulin-like growth factor 1 receptor signaling inhibitors: an in silico drug repurposing study of the regenerating cochlear neuron transcriptome. J Clin Med 12(10):3485. https:\/\/doi.org\/10.3390\/jcm12103485","journal-title":"J Clin Med"},{"issue":"9","key":"10491_CR11","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1210\/clinem\/dgad213","volume":"108","author":"MN Stan","year":"2023","unstructured":"Stan MN, Krieger CC (2023) The adverse effects profile of teprotumumab. J Clin Endocrinol Metab 108(9):e654\u2013e662. https:\/\/doi.org\/10.1210\/clinem\/dgad213","journal-title":"J Clin Endocrinol Metab"},{"issue":"49","key":"10491_CR12","doi-asserted-by":"publisher","first-page":"18104","DOI":"10.1523\/JNEUROSCI.3619-11.2011","volume":"31","author":"T Okano","year":"2011","unstructured":"Okano T, Xuan S, Kelley MW (2011) Insulin-like growth factor signaling regulates the timing of sensory cell differentiation in the mouse cochlea. J Neurosci 31(49):18104\u201318118. https:\/\/doi.org\/10.1523\/JNEUROSCI.3619-11.2011","journal-title":"J Neurosci"},{"issue":"1","key":"10491_CR13","doi-asserted-by":"publisher","first-page":"814891","DOI":"10.3389\/fncel.2021.814891","volume":"15","author":"L Zhang","year":"2022","unstructured":"Zhang L, Chen S, Sun Y (2022) Mechanism and prevention of spiral ganglion neuron degeneration in the cochlea. Front Cell Neurosci 15(1):814891. https:\/\/doi.org\/10.3389\/fncel.2021.814891","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"10491_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/sjopt.sjopt_179_23","volume":"38","author":"H Goldberg","year":"2024","unstructured":"Goldberg H, Malik AI (2024) Teprotumumab in thyroid eye disease. Saudi J Ophthalmol 38(1):29\u201333. https:\/\/doi.org\/10.4103\/sjopt.sjopt_179_23","journal-title":"Saudi J Ophthalmol"},{"issue":"17","key":"10491_CR15","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1007\/s40265-022-01804-1","volume":"82","author":"T Nie","year":"2022","unstructured":"Nie T, Lamb YN (2022) Teprotumumab: a review in thyroid eye disease. Drugs 82(17):1663\u20131670. https:\/\/doi.org\/10.1007\/s40265-022-01804-1","journal-title":"Drugs"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10491-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-026-10491-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10491-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:42:32Z","timestamp":1786336952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-026-10491-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":15,"alternative-id":["10491"],"URL":"https:\/\/doi.org\/10.1007\/s00405-026-10491-7","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there are no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicting interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}